Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Avalo Therapeutics (AVTX) over the last 6 years, with Q3 2025 value amounting to $14.0 million.

  • Avalo Therapeutics' Shares Outstanding (Diluted Average) rose 2982.57% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year increase of 2982.57%. This contributed to the annual value of $34.8 million for FY2018, which is 8541.18% up from last year.
  • Avalo Therapeutics' Shares Outstanding (Diluted Average) amounted to $14.0 million in Q3 2025, which was up 2982.57% from $10.8 million recorded in Q2 2025.
  • In the past 5 years, Avalo Therapeutics' Shares Outstanding (Diluted Average) registered a high of $14.0 million during Q3 2025, and its lowest value of $859381.0 during Q1 2024.